Showing results (131-140 of 437) with videos related to

Sort By:
Pageof 44
Arthritis Research & Therapy|August 18, 2018
High-frequency ultrasound of the skin in systemic sclerosis: an exploratory study to examine correlation with disease activity and to define the minimally detectable differenceHongyan Li, Daniel E Furst, Hongtao Jin, et al.
Arthritis and Rheumatism|June 26, 2008
Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: results of a multicenter, randomized, double-blind, active drug-controlled studyMichael E Weinblatt, Michael H Schiff, Eric M Ruderman, et al.
The Journal of Rheumatology|October 10, 2008
Vitamin D, parathyroid hormone, and acroosteolysis in systemic sclerosisYolanda Braun-Moscovici, Daniel E Furst, Doron Markovits, et al.
Arthritis Care & Research|February 22, 2011
Greater likelihood of remission in rheumatoid arthritis patients treated earlier in the disease course: results from the Consortium of Rheumatology Researchers of North America registryDaniel E Furst, Aileen L Pangan, Leslie R Harrold, et al.
Clinical and Experimental Rheumatology|September 1, 2020
Intravenous versus oral cyclophosphamide for lung and/or skin fibrosis in systemic sclerosis: an indirect comparison from EUSTAR and randomised controlled trialsCosimo Bruni, Donald P Tashkin, Virginia Steen, et al.
Arthritis and Rheumatism|July 27, 2012
Effect of nonsteroidal antiinflammatory drugs on the C-reactive protein level in rheumatoid arthritis: a meta-analysis of randomized controlled trialsSimon Tarp, Else M Bartels, Henning Bliddal, et al.
Arthritis Research & Therapy|August 25, 2022
Association between low hemoglobin, clinical measures, and patient-reported outcomes in patients with rheumatoid arthritis: results from post hoc analyses of three phase III trials of sarilumabAndrea Rubbert-Roth, Daniel E Furst, Stefano Fiore, et al.
The Journal of Rheumatology|March 23, 2002
Dose response and safety study of meloxicam up to 22.5 mg daily in rheumatoid arthritis: a 12 week multicenter, double blind, dose response study versus placebo and diclofenacDaniel E Furst, Karen S Kolba, Roy Fleischmann, et al.
Clinical Rheumatology|March 12, 2018
Ultrasound characterization of cutaneous ulcers in systemic sclerosisYossra A Suliman, Suzanne Kafaja, John Fitzgerald, et al.
Arthritis Care & Research|August 5, 2015
Certolizumab Pegol Efficacy Across Methotrexate Regimens: A Pre-Specified Analysis of Two Phase III TrialsBernard Combe, Daniel E Furst, Edward C Keystone, et al.
Pageof 44